GlassScriptPhysician profile
Cecelia Virgil
NPI 1063489334
$2,535.10
in general payments reported to CMS, 2019-2025
32 companies · $700 in 2025
The $700 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $411 · 2022: $103 · 2023: $630 · 2024: $692 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,864 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,863.71 |
| Education | $157.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $349.54 | 2021-2025 | Rybrevant, Carvykti, Erleada |
| Incyte Corporation | $304.94 | 2021-2025 | Jakafi |
| Pfizer INC. | $228.84 | 2021-2025 | |
| Beigene USA, INC. | $162.47 | 2023-2024 | Brukinsa |
| Astellas Pharma US INC | $117.81 | 2021-2023 | Xtandi |
| Novartis Pharmaceuticals Corporation | $116.01 | 2022-2024 | |
| Dova Pharmaceuticals | $113.34 | 2021 | |
| Medtronic, INC. | $113.31 | 2025 | Venaseal |
| Sanofi-Aventis U.S. LLC | $95.00 | 2024 | |
| Merck Sharp & Dohme LLC | $83.94 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Eisai INC. | $78.31 | 2024-2025 | |
| Daiichi Sankyo INC. | $66.91 | 2024-2025 | Enhertu, Datroway |
| Genentech USA, INC. | $63.94 | 2024-2025 | Tecentriq, Polivy |
| Genzyme Corporation | $59.94 | 2022-2024 | |
| Exelixis INC. | $58.86 | 2025 | Cabometyx |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $53.43 | 2023-2024 | Iclusig, Alunbrig |
| Astrazeneca Pharmaceuticals LP | $46.81 | 2023-2024 | Tagrisso |
| Lilly USA, LLC | $46.65 | 2023-2024 | Jaypirca, Verzenio |
| Mirati Therapeutics, INC. | $45.71 | 2023 | Krazati |
| Celgene Corporation | $45.42 | 2021-2023 | Reblozyl |
| Adaptive Biotechnologies Corporation | $31.62 | 2023 | Clonoseq |
| Legend Biotech USA INC. | $31.44 | 2024-2025 | Carvykti |
| Alexion Pharmaceuticals, INC. | $29.91 | 2025 | Ultomiris |
| Aveo Pharmaceuticals, INC. | $26.09 | 2023 | Fotivda |
| Glaxosmithkline, LLC. | $25.45 | 2025 | Zejula, Jemperli |
| Ipsen Biopharmaceuticals, INC | $24.65 | 2023 | Tazverik |
| Seagen INC. | $22.48 | 2023 | Padcev |
| Tersera Therapeutics LLC | $20.68 | 2023 | Zoladex |
| Jazz Pharmaceuticals INC. | $20.18 | 2025 | |
| Emd Serono, INC. | $20.00 | 2023 | Bavencio |
| Bayer Healthcare Pharmaceuticals INC. | $18.12 | 2025 | |
| Array Biopharma INC | $13.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecelia Virgil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.